Jan 11, 2022 / 07:15PM GMT
Tycho W. Peterson - JPMorgan Chase & Co, Research Division - Senior Analyst
Good afternoon, everybody. I'm Tycho Peterson from the life science team. It's my pleasure to introduce our next company this afternoon, Myriad Genetics. (Operator Instructions)
And with that, let me turn it over to Paul.
Paul J. Diaz - Myriad Genetics, Inc. - CEO, President & Director
Well, thank you, Tycho. Very much appreciate the opportunity to be here and really our 25-year relationship with JPMorgan.
Before we begin, I want to remind everyone that we'll be making certain forward-looking statements during the course of the presentation and referring to certain non-GAAP financial measures, and we encourage you to visit our website for additional information about the company, including our public filings.
So important to begin and emphasize the commitment that we have to being part of a health care system that we see as becoming increasingly patient centered and focused on wellness, prevention and engaging patients and providers with better tools
Myriad Genetics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers